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C O M M E N T A R Y
Fondaparinux in heparin- induced thrombocytopenia:  






Fondaparinux	 is	 an	 antithrombin-	dependent,	 synthetic	 anti-	factor	
Xa-	inhibitor	that	is	used	off-	label	as	an	alternative	anticoagulant	in	
the	 treatment	 of	 life-	threatening	 immune	 heparin-	induced	 throm-







alternative	anticoagulants	 for	 treating	 this	condition	have	clear	 lim-







these	drugs	require	continuous	 IV	 infusion	and	frequent	 laboratory	
monitoring;	(iv)	argatroban,	bivalirudin,	and	danaparoid	use	is	expen-






In	order	 to	 increase	 the	validity	of	 their	 study,	Dr.	 Linkins	 and	
colleagues	 have	 applied	 strict	 inclusion	 and	 exclusion	 criteria	 (ie,	
fondaparinux	 as	 primary	 anticoagulant	 with	 no	 other	 alternative	
anticoagulant	 allowed	 for	 >24	hours;	 sufficient	 case	 number	 (≥5	
patients);	 laboratory	 confirmation	 of	HIT	 (serotonin-	release	 assay,	
heparin-	induced	platelet	activation	assay,	or	enzyme-	linked	 immu-
nosorbent	assay),	in	combination	with	clinical	symptoms	consistent	
















Different	 mechanisms	 of	 action,	 eg,	 direct	 oral	 factor	 Xa	 or	
thrombin	inhibition,	could	overcome	the	rare,	but	potential	limitation	
of	fondaparinux	to	cause	HIT	itself,9	and	direct	oral	anticoagulants	
have been widely available. However, the authors of this review have 
already	reported	the	same	difficulties	of	 identifying	and	recruiting	
HIT	patients	for	a	robust	prospective	trial	using	direct	oral	antico-
agulants	 that	 already	 apply	 for	 fondaparinux.10	 Together	with	 the	
manufacturer’s	lack	of	interest	in	investing	into	research	to	expand	
indications	this	will	pose	the	same	problem	as	already	observed	with	
fondaparinux:	 there	might	 be	 no	RCTs	 of	 high	 quality	 available	 in	
the	future	and	gathering	clinical	experience	with	direct	oral	antico-
agulants	to	the	same	extent	as	for	fondaparinux	 is	expanding	only	
slowly.	 Thus,	 the	 data	 presented	 by	 the	 authors	 of	 a	 comparable	
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The	 authors’	 compilation	 of	 clinical	 data	 on	 HIT	 management	
with	 fondaparinux	might	 help	 to	 harmonize	 current	 treatment	 rec-
ommendations.	Looking	at	the	different	guideline	recommendations	
from	various	professional	or	governmental	associations	reveals	that	
these	differ	not	only	 in	methodological	 aspects	but	as	well	 in	 their	
conclusions drawn.11	While	some	guidelines	recommend	the	use	of	
fondaparinux,12–14	 fondaparinux	carries	 a	 level	2C	 recommendation	
from	the	American	College	of	Chest	Physicians	 (ACCP).15 However, 
ACCP	 held	 out	 the	 prospect	 of	 readjusting	 their	 recommendations	

















thrombocytopenia	 (HIT),21	 after	 this	writing,	 recommended	 the	 use	
of	fondaparinux	in	the	treatment	of	acute	HIT	with	thromboembolic	
complications.	Despite	the	reference	to	the	very	low		certainty	in	the	
evidence	about	effects,	 no	preference	 is	 suggested	 for	non-heparin	
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